While these studies clinically validated the use of TMEM Score for prognosticating metastatic outcome in HR+/HER2− patients (the largest subgroup of breast cancer patients), a statistically significant association between TMEM Score and distant recurrence outcome was not observed in the triple-negative or HER2+ breast cancer subpopulations, perhaps due to the smaller number of these subjects available for analysis. The gene discussed is ERBB2; the disease is breast cancer.